CARE Ratings Limited has informed the Exchange regarding a press release dated May 12, 2025, titled "Press Release ".
CARERATING · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 11.8 pts more than Nifty Microcap 250 and 12.2 pts more than its Capital Markets peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
CARE Ratings reported its highest-ever standalone and consolidated income from operations for FY25, with standalone revenue rising 19% YoY to Rs. 336.7 crore and consolidated revenue growing 21% to Rs. 402.3 crore. Standalone PAT increased 24% to Rs. 147.9 crore, while consolidated PAT jumped 37% to Rs. 140 crore, with consolidated EBITDA margin expanding sharply from 34% to 39%, driven by stronger subsidiary performance. Q4 FY25 was particularly strong, with consolidated PAT up 77% YoY to Rs. 43.4 crore and EBITDA up 63%. The Ratings business grew 21% to Rs. 360.1 crore while the Non-Ratings business surged 27% to Rs. 42.2 crore. The Board recommended a final dividend of Rs. 11 per share, taking the total FY25 dividend to Rs. 18 per share on a Rs. 10 face value.
Strong all-round results with high-teens to mid-30s growth across revenue, EBITDA, and PAT, plus meaningful margin expansion and a healthy dividend, are likely to be viewed positively by shareholders and could support the stock price.